Acute Myeloid Leukemia

Antiangiogenic affect of purine analogs may help in hematological cancers

Published in Cancer Weekly, September 24th, 2002

by Sonia Nichols, senior medical writer - Data collected in a new study has made researchers suspect that purine analogs used for treating acute myelogenous or myeloid leukemia (AML) may have antiangiogenic properties in addition to cytotoxic properties.

Research investigators at the University of Brescia in Italy have tested the effects of the antimetabolite 6-thioguanine (6-TG) on hematological cancers in vitro and in vivo, only to find that in addition to altering tumor metabolism, drugs of its type may also alter tumor-associated vascularization.

"6-TG inhibited endothelial cell proliferation triggered by fibroblast growth factor-2 (FGF-2) and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-09-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry